Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
This article was originally published in PharmAsia News
Executive Summary
Takeda announced June 27 that U.S. FDA had denied approval of its type 2 diabetes agent alogliptin, a potential blockbuster poised to compete with similar molecules from Merck and the team of Bristol-Myers Squibb and AstraZeneca. The setback will delay alogliptin's launch by at least three years - and possibly longer - depending on the additional studies required by regulators